RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 Antibodies Among Rural Healthcare Workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.07.21258375
DO 10.1101/2021.06.07.21258375
A1 Jordan Z. Neises
A1 Md Saddam Hossain
A1 Rifat Sultana
A1 Kevin N. Wanniarachchi
A1 Jared W. Wollman
A1 Eric Nelson
A1 Bonny L. Specker
A1 Adam D. Hoppe
A1 Steven R. Lawson
A1 Natalie W. Thiex
YR 2021
UL http://medrxiv.org/content/early/2021/06/08/2021.06.07.21258375.abstract
AB The objective of this longitudinal cohort study was to determine the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in healthcare workers employed at healthcare clinics in three rural counties in eastern South Dakota and western Minnesota from May 13, 2020 through December 22, 2020. Three blood draws were performed at five clinical sites and tested for the presence of antibodies against the SARS-CoV-2 virus. Serum samples were tested for the presence of antibodies using a fluorescent microsphere immunoassay (FMIA), neutralization of SARS-CoV-2 Spike-pseudotyped particles (SARS-CoV-2pp) assay, and serum virus neutralization (SVN) assay. The seroprevalence was determined to be 1/336 (0.29%) for samples collected from 5/13/20-7/13/20, 5/260 (1.92%) for samples collected from 8/13/20-9/25/20, and 35/235 (14.89%) for samples collected from 10/16/20-12/22/20. Eight of the 35 (22.8%) seropositive individuals identified in the final draw did not report a previous diagnosis with COVID-19. There was a high correlation (>90%) among the FMIA and virus neutralization assays. Each clinical site’s seroprevalence was higher than the cumulative incidence for the general public in each respective county as reported by state public health agencies. As of December 2020, there was a high percentage (85%) of seronegative individuals in the study population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSouth Dakota Governor's Office of Economic Development, BioSNTRAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subjects procedures were approved by the South Dakota State University Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.